Analysts take a look at Sarepta Therapeutics Inc (NASDAQ:SRPT) having this to say.

July 18, 2017 - By Hazel Jackson

 Analysts take a look at Sarepta Therapeutics Inc (NASDAQ:SRPT) having this to say.
Investors sentiment decreased to 1.07 in Q4 2016. Its down 0.45, from 1.52 in 2016Q3. It turned negative, as 42 investors sold Sarepta Therapeutics Inc shares while 46 reduced holdings. 39 funds opened positions while 55 raised stakes. 38.63 million shares or 7.09% less from 41.57 million shares in 2016Q3 were reported.
The Connecticut-based Paloma Prtn Mngmt has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Stifel holds 11,201 shares or 0% of its portfolio. Venbio Select Advisor Lc stated it has 1.01 million shares. Moreover, Balyasny Asset Ltd Limited Liability Company has 0.03% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT). Hanson Mcclain holds 399 shares or 0% of its portfolio. Goldman Sachs Gru invested in 238,363 shares or 0% of the stock. Swiss Bank & Trust accumulated 82,200 shares or 0% of the stock. Wells Fargo And Mn has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT). Blackrock accumulated 117,536 shares. 839,342 were reported by Jefferies Group Inc Ltd Liability Corp. Deutsche Financial Bank Ag holds 0.01% or 314,364 shares. Hightower Advsrs Ltd Liability Company invested in 41,350 shares or 0.01% of the stock. Perceptive Advsr Ltd Liability Corp has invested 5.41% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Highbridge Management Limited Company stated it has 0.02% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT). Public Employees Retirement Association Of Colorado holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 10,545 shares.

Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage

Among 24 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Sarepta Therapeutics had 65 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Wedbush given on Thursday, April 21. Roth Capital maintained the shares of SRPT in report on Wednesday, August 5 with “Buy” rating. RBC Capital Markets upgraded the stock to “Outperform” rating in Monday, September 19 report. TH Capital maintained the stock with “Buy” rating in Wednesday, August 26 report. The firm earned “Neutral” rating on Wednesday, April 20 by Janney Capital. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Neutral” rating given on Friday, August 7 by Suntrust Robinson. Wedbush maintained the shares of SRPT in report on Monday, October 10 with “Outperform” rating. Wedbush maintained Sarepta Therapeutics Inc (NASDAQ:SRPT) rating on Wednesday, July 20. Wedbush has “Outperform” rating and $36 target. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, April 6. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, March 1. Below is a list of Sarepta Therapeutics Inc (NASDAQ:SRPT) latest ratings and price target changes.

28/06/2017 Broker: Credit Suisse Rating: Buy New Target: $64.0000 Maintain
21/06/2017 Broker: RBC Capital Markets Rating: Buy New Target: $60.0000 Maintain
07/06/2017 Broker: Oppenheimer Rating: Buy New Target: $76.0000 Maintain
05/04/2017 Broker: SunTrust Old Rating: Hold New Rating: Buy Upgrade
02/03/2017 Broker: Nomura Rating: Buy Initiates Coverage On
02/03/2017 Broker: Leerink Swann Old Rating: Market Perform New Rating: Outperform Old Target: $27.00 New Target: $47.00 Upgrade
01/03/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: $98 New Target: $91 Maintain
22/02/2017 Broker: Needham Rating: Buy Old Target: $81 New Target: $78 Maintain

About 47,152 shares traded. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 96.82% since July 18, 2016 and is uptrending. It has outperformed by 80.12% the S&P500.

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $1.90 billion. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. It currently has negative earnings. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Globenewswire.com which released: “Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief …” on June 28, 2017, also Nasdaq.com with their article: “SRPT Makes Bullish Cross Above Critical Moving Average” published on July 13, 2017, Marketwatch.com published: “Sarepta Therapeutics names new CEO” on June 28, 2017. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017” published on June 30, 2017 as well as Globenewswire.com‘s news article titled: “Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a …” with publication date: July 18, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.